ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2011
Mycoplasma genitalium: should we treat and how?
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.
- Sexually transmitted diseases treatment guidelines, 2015.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2015Guideline
- Mycoplasma genitalium Infection in Kenyan and US Women.Sexually transmitted diseases · 2018Trial
- Trial
- Comparative Epidemiology and Co-Detection ofPathogens (Basel, Switzerland) · 2026Article
- Novel Multiplex Near-Point-of-Care PCR Assay for Detecting Sexually Transmitted Infections Among PrEP Users in Western Kenya: Protocol for a Cross-Sectional Pilot Study With an Epidemiological Assessment.JMIR research protocols · 2026Article
- Cost of illness of Mycoplasma genitalium in Australia: an incidence-based approach incorporating resistance-guided therapy.Scientific reports · 2026Article
- Mathematical analysis of Mycoplasma Genitalium transmission dynamics: A compartmental model with nonlinear interactions and treatment effects.PLOS global public health · 2026Article
- Distribution and resistance patterns of male urethritis pathogens from a private South African laboratory.World journal of urology · 2025Article
- Development of human mycoplasma vaccines: navigating the IL-17A paradox.Frontiers in immunology · 2025Review
- To Screen or Not to Screen-Controversies in Testing forJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2024Article
- Article
- Cost-effectiveness of resistance-guided therapy for Mycoplasma genitalium in Australia.Scientific reports · 2024Article
- Prevalence of Mollicutes among men who have sex with men and transgender women aged 15 to 19 years in Salvador, North-eastern Brazil.BMC infectious diseases · 2023Article
- Prevalence ofHealthcare (Basel, Switzerland) · 2023Article
- Pathogenicity and virulence ofVirulence · 2022Review
- Ascending Reproductive Tract Infection in Pig-Tailed Macaques Inoculated with Mycoplasma genitalium.Infection and immunity · 2022Article
- Azithromycin and Doxycycline Resistance Profiles of U.S. Mycoplasma genitalium Strains and Their Association with Treatment Outcomes.Journal of clinical microbiology · 2021Article
- Integrating the Human and Animal Sides of Mycoplasmas Resistance to Antimicrobials.Antibiotics (Basel, Switzerland) · 2021Review
- Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections.Antibiotics (Basel, Switzerland) · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Mycoplasma genitalium is associated with acute and chronic urethritis in men. Existing data on infection in women are limited and inconsistent but suggest that M. genitalium is associated with urethritis, cervicitis, pelvic inflammatory disease, and possibly female infertility. Data are inconclusive regarding the role of M. genitalium in adverse pregnancy outcomes and ectopic pregnancy. Available data suggest that azithromycin is superior to doxycycline in treating M. genitalium infection. However, azithromycin-resistant infections have been reported in 3 continents, and the proportion of azithromycin-resistant M. genitalium infection is unknown. Moxifloxacin is the only drug that currently seems to uniformly eradicate M. genitalium. Detection of M. genitalium is hampered by the absence of a commercially available diagnostic test. Persons with persistent pelvic inflammatory disease or clinically significant persistent urethritis or cervicitis should be tested for M. genitalium, if possible. Infected persons who have not previously received azithromycin should receive that drug. Persons in whom azithromycin therapy fails should be treated with moxifloxicin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.